Objective To observe the value of deep learning echocardiographic intelligent model for evaluation on left ventricular(LV)regional wall motion abnormalities(RWMA).Methods Apical two-chamber,three-chamber and four-cham...Objective To observe the value of deep learning echocardiographic intelligent model for evaluation on left ventricular(LV)regional wall motion abnormalities(RWMA).Methods Apical two-chamber,three-chamber and four-chamber views two-dimensional echocardiograms were obtained prospectively in 205 patients with coronary heart disease.The model for evaluating LV regional contractile function was constructed using a five-fold cross-validation method to automatically identify the presence of RWMA or not,and the performance of this model was assessed taken manual interpretation of RWMA as standards.Results Among 205 patients,RWMA was detected in totally 650 segments in 83 cases.LV myocardial segmentation model demonstrated good efficacy for delineation of LV myocardium.The average Dice similarity coefficient for LV myocardial segmentation results in the apical two-chamber,three-chamber and four-chamber views was 0.85,0.82 and 0.88,respectively.LV myocardial segmentation model accurately segmented LV myocardium in apical two-chamber,three-chamber and four-chamber views.The mean area under the curve(AUC)of RWMA identification model was 0.843±0.071,with sensitivity of(64.19±14.85)%,specificity of(89.44±7.31)%and accuracy of(85.22±4.37)%.Conclusion Deep learning echocardiographic intelligent model could be used to automatically evaluate LV regional contractile function,hence rapidly and accurately identifying RWMA.展开更多
探讨达格列净是否能够改善糖尿病合并收缩功能保留心衰患者症状及对sST2水平影响。方法:连续选取2019年4月至2021年4月在淮安市第二人民医院就诊的糖尿病合并收缩功能保留心衰患者109例,随机分为治疗组(达格列净联合常规药物治疗,54例)...探讨达格列净是否能够改善糖尿病合并收缩功能保留心衰患者症状及对sST2水平影响。方法:连续选取2019年4月至2021年4月在淮安市第二人民医院就诊的糖尿病合并收缩功能保留心衰患者109例,随机分为治疗组(达格列净联合常规药物治疗,54例)及对照组( 常规药物治疗, 55例)。常规药物治疗严格遵循2017年加拿大心脏病学会推荐的治疗舒张性心力衰竭药物,包括血管紧张素转化酶抑制剂(ACEI)、管紧张素受体阻滞剂(ARB)或血管紧张素受体-脑啡肽酶抑制剂(ARNI)、β受体阻滞剂、螺内酯。达格列净口服,10mg/d,共8周。观察治疗前后N末端B型利钠肽原(NT-proBNP)及血清可溶性人基质裂解素2(sST2)水平,6分钟步行距离,以及心脏彩超左心室舒张功能等指标变化。结果:达格列净组与对照组相比显著降低了左室舒张功能不全(E/A, 达格列净治疗后 vs 对照组治疗后,1.9±0.5 vs 2.2±0.9 , P<0.05 ),进一步增加了患者运动能力(达格列净治疗后 vs 对照组治疗后,388.1±71.5 vs 350.6±71.2(m),P<0.01),更加显著降低了NT-proBNP及sST2水平。结论:达格列净联合常规药物治疗进一步改善了糖尿病合并收缩功能保留心衰患者运动耐量,提高了6分钟步行距离,降低了NT-proBNP及sST2水平。展开更多
文摘Objective To observe the value of deep learning echocardiographic intelligent model for evaluation on left ventricular(LV)regional wall motion abnormalities(RWMA).Methods Apical two-chamber,three-chamber and four-chamber views two-dimensional echocardiograms were obtained prospectively in 205 patients with coronary heart disease.The model for evaluating LV regional contractile function was constructed using a five-fold cross-validation method to automatically identify the presence of RWMA or not,and the performance of this model was assessed taken manual interpretation of RWMA as standards.Results Among 205 patients,RWMA was detected in totally 650 segments in 83 cases.LV myocardial segmentation model demonstrated good efficacy for delineation of LV myocardium.The average Dice similarity coefficient for LV myocardial segmentation results in the apical two-chamber,three-chamber and four-chamber views was 0.85,0.82 and 0.88,respectively.LV myocardial segmentation model accurately segmented LV myocardium in apical two-chamber,three-chamber and four-chamber views.The mean area under the curve(AUC)of RWMA identification model was 0.843±0.071,with sensitivity of(64.19±14.85)%,specificity of(89.44±7.31)%and accuracy of(85.22±4.37)%.Conclusion Deep learning echocardiographic intelligent model could be used to automatically evaluate LV regional contractile function,hence rapidly and accurately identifying RWMA.
文摘探讨达格列净是否能够改善糖尿病合并收缩功能保留心衰患者症状及对sST2水平影响。方法:连续选取2019年4月至2021年4月在淮安市第二人民医院就诊的糖尿病合并收缩功能保留心衰患者109例,随机分为治疗组(达格列净联合常规药物治疗,54例)及对照组( 常规药物治疗, 55例)。常规药物治疗严格遵循2017年加拿大心脏病学会推荐的治疗舒张性心力衰竭药物,包括血管紧张素转化酶抑制剂(ACEI)、管紧张素受体阻滞剂(ARB)或血管紧张素受体-脑啡肽酶抑制剂(ARNI)、β受体阻滞剂、螺内酯。达格列净口服,10mg/d,共8周。观察治疗前后N末端B型利钠肽原(NT-proBNP)及血清可溶性人基质裂解素2(sST2)水平,6分钟步行距离,以及心脏彩超左心室舒张功能等指标变化。结果:达格列净组与对照组相比显著降低了左室舒张功能不全(E/A, 达格列净治疗后 vs 对照组治疗后,1.9±0.5 vs 2.2±0.9 , P<0.05 ),进一步增加了患者运动能力(达格列净治疗后 vs 对照组治疗后,388.1±71.5 vs 350.6±71.2(m),P<0.01),更加显著降低了NT-proBNP及sST2水平。结论:达格列净联合常规药物治疗进一步改善了糖尿病合并收缩功能保留心衰患者运动耐量,提高了6分钟步行距离,降低了NT-proBNP及sST2水平。
